Investor Newsletters - "We have a pivotal few months ahead of us in the lead-up to results from XanADu, and we are making every effort to engage key stakeholders ahead of the read-out from this important global trial. As you can see from this newsletter, our team will be attending a number of high-profile investor and scientific conferences over the next few months to present our work. Also, the team will be making a concerted effort to engage with the media and raise awareness of Actinogen Medical.

Twitter -Actinogen Medical‏ @ActinogenMed2h2 hours ago

@BillKetelbey will provide an update on #Actinogen progress at the 2nd Annual Sachs Neuroscience Innovation Forum in San Francisco on Sun 6 Jan 2019 2.10pm PS

Sachs Neuroscience Innovation Forum

"For BD&L and Investment in Therapeutics and Technology"
Building on the success of our last year's forum we are pleased to announce The 2nd Annual Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and Technology to take place at the Marines' Memorial Club, San Francisco on the 6th of January 2019, a day before the JP Morgan meeting. The program will cover BioPartnering for CNS, with industry keynotes and panels on AD, PD, Neuropsychiatry and Pain Management. Moreover there are panels on innovation in NeuroTech covering banking, device, diagnostics and software. The target audience are buy and sell side analysts from investment banks and funds and partnering executives from pharma and medtech companies. We anticipate around 200 delegates and 25+ company presentations by established public, private and emerging companies. There are numerous networking opportunities available via an online One-2-One meeting system with dedicated meeting facilities to make the event more transactional.

https://10times.com/neuroscience-technology-innovation-forum